Information updates

Anapen® now approved for 3 seconds

The time for Anapen® adrenaline (epinephrine) autoinjectors to be held in place has now been approved for 3 seconds (reduced from 10 seconds) by the Therapeutic Goods Administration (TGA).

Whilst the time has reduced from 10 to 3 seconds, Anapen® devices have not changed. This reduction is based on data that confirms efficacy and delivery of adrenaline through the 3 second time frame.

All Anapen® devices should now be held in place for 3 seconds, regardless of the instructions on the label.  However, if they are held for 10 seconds it will not affect the way that the adrenaline works. 

Anapen® devices with the 3 second label are expected to enter pharmacies in Australia from January 2023 onwards. In the meantime, Anapen® devices with a 10 second label can continue to be used, and injected for 3 seconds. Anapen® devices should not be replaced unless they have been used, are just about to expire or have expired.  

To access the updated Anapen® versions of the ASCIA Action Plan for Anaphylaxis (red) and ASCIA First Aid Plan for Anaphylaxis (orange) go to 

ASCIA anaphylaxis e-training courses have been revised to include the updated Anapen® version of the ASCIA Action Plan for Anaphylaxis and instructions. To access the courses go to 

Information is also available on the Anapen website which has been updated to include a 3-D animation and the option of entering product expiry so a reminder to renew can be received. The reminder email will be sent one month prior to expiry.

The Anapen® version of the ASCIA Action Plan for Anaphylaxis (red) is provided to people with allergies who have been prescribed Anapen® adrenaline autoinjectors, which have been available on the PBS in Australia since September 2021. In September 2022 the TGA has approved Anapen® to be held in place for 3 seconds (reduced from 10 seconds). 

Anapen®  doses recommended by ASCIA:

  1. Anapen® 150 (Jr): Children 7.5-20 kg (~1-5 yr)
  2. Anapen® 300: Adults or children >20kg (>5 yr)
  3. Anapen® 500: Adults or children >50kg (>12 yr)

This news item was issued on 9 September 2022 and updated on 19 October by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand.   

Mod ASCIA Member
Donate to AIFA
go to NAC website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia